Nonalcoholic Fatty Liver Disease

References

1. ↵
   1. Chalasani N,
   2. Younossi Z,
   3. Lavine JE, et al., American Gastroenterological Association, American Association for the Study of Liver Diseases, American College of Gastroenterology

   The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592-1609.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. Day CP

   Non-alcoholic fatty liver disease: a massive problem. Clin Med (Lond). 2011;11(2):176-178.

   OpenUrlPubMed
3. ↵
   1. Angulo P

   Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221-1231.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   1. Newton JL,
   2. Jones DE,
   3. Henderson E, et al.

   Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut. 2008;57(6):807-813.

   OpenUrlAbstract/FREE Full Text
5. ↵
   1. Mofrad P,
   2. Contos MJ,
   3. Haque M, et al.

   Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37(6):1286-1292.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Ong JP,
   2. Pitts A,
   3. Younossi ZM

   Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008;49(4):608-612.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Stepanova M,
   2. Rafiq N,
   3. Makhlouf H, et al.

   Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58(10):3017-3023.

   OpenUrlCrossRefPubMed
8. ↵
   1. Argo CK,
   2. Northup PG,
   3. Al-Osaimi AM,
   4. Caldwell SH

   Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009;51(2):371-379.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Sanyal AJ,
   2. Banas C,
   3. Sargeant C, et al.

   Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006;43(4):682-689.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Adams LA,
    2. Lymp JF,
    3. St Sauver J, et al.

    The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113-121.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Nalbantoglu IL,
    2. Brunt EM

    Role of liver biopsy in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(27):9026-9037.

    OpenUrlPubMed
12. ↵
    1. Ratziu V,
    2. Bellentani S,
    3. Cortez-Pinto H,
    4. Day C,
    5. Marchesini G

    A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53(2):372-384.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    1. Huang MA,
    2. Greenson JK,
    3. Chao C, et al.

    One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol. 2005;100(5):1072-1081.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    1. Gasteyger C,
    2. Larsen TM,
    3. Vercruysse F,
    4. Astrup A

    Effect of a dietary-induced weight loss on liver enzymes in obese subjects. Am J Clin Nutr. 2008;87(5):1141-1147.

    OpenUrlAbstract/FREE Full Text
15. 1. Promrat K,
    2. Kleiner DE,
    3. Niemeier HM, et al.

    Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1):121-129.

    OpenUrlCrossRefPubMedWeb of Science
16. ↵
    1. Hickman IJ,
    2. Jonsson JR,
    3. Prins JB, et al.

    Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004;53(3):413-419.

    OpenUrlAbstract/FREE Full Text
17. ↵
    1. Promrat K,
    2. Kleiner DE,
    3. Niemeier, et al.

    Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1):121-129.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    1. Mummadi RR,
    2. Kasturi KS,
    3. Chennareddygari S,
    4. Sood GK

    Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6(12):1396-1402.

    OpenUrlCrossRefPubMedWeb of Science
19. ↵
    1. Day CP

    From fat to inflammation. Gastroenterology. 2006;130(1):207-210.

    OpenUrlCrossRefPubMedWeb of Science
20. 1. Angulo P,
    2. Machado MV,
    3. Diehl AM

    Fibrosis in nonalcoholic fatty liver disease: mechanisms and clinical implications. Semin Liver Dis. 2015;35(2):132-145.

    OpenUrlCrossRefPubMed
21. ↵
    1. Boursier J,
    2. Diehl AM

    Implication of gut microbiota in nonalcoholic fatty liver disease. PLoS Pathog. 2015;11(1):e1004559.

    OpenUrlPubMed
22. ↵
    1. Ratziu V,
    2. Giral P,
    3. Jacqueminet S, et al., LIDO Study Group

    Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008;135(1):100-110.

    OpenUrlCrossRefPubMedWeb of Science
23. 1. Aithal GP,
    2. Thomas JA,
    3. Kaye PV, et al.

    Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135(4):1176-1184.

    OpenUrlCrossRefPubMedWeb of Science
24. 1. Sanyal AJ,
    2. Chalasani N,
    3. Kowdley KV, et al., NASH CRN

    Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-1685.

    OpenUrlCrossRefPubMedWeb of Science
25. 1. Belfort R,
    2. Harrison SA,
    3. Brown K, et al.

    A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355(22):2297-2307.

    OpenUrlCrossRefPubMedWeb of Science
26. ↵
    1. Torres DM,
    2. Jones FJ,
    3. Williams CD,
    4. Harrison S

    The effect of 48 weeks of rosiglitazone alone versus combination rosiglitazone and metformin (Avandamet) versus combination rosiglitzone and losartan in treatment of nonalcoholic steatohepatitis (NASH): a open-label prospective randomized clinical trial. Hepatology. 2009;50(4):390A-319A.

    OpenUrl
27. ↵
    1. Sanyal AJ,
    2. Chalasani N,
    3. Kowdley KV, et al., NASH CRN

    Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-1685.

    OpenUrlCrossRefPubMedWeb of Science
28. ↵
    1. Neuschwander-Tetri BA,
    2. Loomba R,
    3. Sanyal AJ, et al., NASH Clinical Research Network

    Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956-965.

    OpenUrlCrossRefPubMed
29. ↵
    1. Laurin J,
    2. Lindor KD,
    3. Crippin JS, et al.

    Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology. 1996;23(6):1464-1467.

    OpenUrlCrossRefPubMedWeb of Science
30. ↵
    1. Vuppalanchi R,
    2. Chalasani N

    Statins for hyperlipidemia in patients with chronic liver disease: are they safe? Clin Gastroenterol Hepatol. 2006;4(7):838-839.

    OpenUrlCrossRefPubMedWeb of Science
31. ↵
    1. Bugianesi E,
    2. Gentilcore E,
    3. Manini R, et al.

    A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005;100(5):1082-1090.

    OpenUrlCrossRefPubMedWeb of Science